Cargando…

Quality of T-cell responses versus reduction in viral load: results from an exploratory phase II clinical study of Vacc-4x, a therapeutic HIV vaccine

Detalles Bibliográficos
Autores principales:	Ellefsen-Lavoie, K, Rockstroh, J, Pollard, R, Pantaleo, G, Podzamczer, D, Asmuth, D, van Lunzen, J, Arastéh, K, Schürmann, D, Peters, B, Clotet, B, Hardy, D, Lazzarin, A, Gatell, J, Sommerfelt, MA, Baksaas, I, Wendel-Hansen, V, Sørensen, B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441273/ http://dx.doi.org/10.1186/1742-4690-9-S2-O66

Ejemplares similares

Re-boost immunizations with the peptide-based therapeutic HIV vaccine, Vacc-4x, restores geometric mean viral load set-point during treatment interruption
por: Rockstroh, Jürgen K., et al.
Publicado: (2019)

P18-14 LB. Vacc-4x HIV p24-like peptide vaccine-associated increase of CD4 T-cells in chronically infected HIV-1 patients on antiretroviral therapy
por: Bengtsson, P, et al.
Publicado: (2009)

The Vacc-SeqQC project: Benchmarking RNA-Seq for clinical vaccine studies
por: Goll, Johannes B., et al.
Publicado: (2023)

Intranasal Administration of a Therapeutic HIV Vaccine (Vacc-4x) Induces Dose-Dependent Systemic and Mucosal Immune Responses in a Randomized Controlled Trial
por: Brekke, Kristin, et al.
Publicado: (2014)

Corrigendum: The Vacc-SeqQC project: Benchmarking RNA-Seq for clinical vaccine studies
por: Goll, Johannes B., et al.
Publicado: (2023)

VaccImm: simulating peptide vaccination in cancer therapy
por: von Eichborn, Joachim, et al.
Publicado: (2013)

The therapeutic HIV Env C5/gp41 vaccine candidate Vacc-C5 induces specific T cell regulation in a phase I/II clinical study
por: Brekke, Kristin, et al.
Publicado: (2017)

The Vaccination Concerns in COVID-19 Scale (VaCCS): Development and validation
por: Hamilton, Kyra, et al.
Publicado: (2022)

Decentralized Open Platform for Vaccination—A German Example: COVID-19-Vacc
por: Radonjic-Simic, Mirjana, et al.
Publicado: (2021)

Development of Immune-Specific Interaction Potentials and Their Application in the Multi-Agent-System VaccImm
por: Woelke, Anna Lena, et al.
Publicado: (2011)

Outgroup emotion processing in the vACC is modulated by childhood trauma and CACNA1C risk variant
por: Krautheim, Johannes T, et al.
Publicado: (2018)

Long-term outcomes of switching to fixed-dose abacavir/lamivudine (ABC/3TC) or tenofovir/emtricitabine (TDF/FTC): 3-year results of the BICOMBO study
por: Martínez, E, et al.
Publicado: (2010)

Parents’ intention to vaccinate their child for COVID-19: A mixed-methods study (CoVAccS–wave 3)
por: Smith, Louise E., et al.
Publicado: (2022)

Cell-Mediated Immune Predictors of Vaccine Effect on Viral Load and CD4 Count in a Phase 2 Therapeutic HIV-1 Vaccine Clinical Trial
por: Huang, Yunda, et al.
Publicado: (2017)

Genetic characterization of the HIV-1 reservoir after Vacc-4x and romidepsin therapy in HIV-1-infected individuals
por: Winckelmann, Anni, et al.
Publicado: (2018)

COVID-19 vaccination acceptability in the UK at the start of the vaccination programme: a nationally representative cross-sectional survey (CoVAccS – wave 2)
por: Sherman, S.M., et al.
Publicado: (2022)

A pilot study to determine the prevalence of HIV in persons presenting for care with selected conditions: preliminary results from the HIV in Europe study
por: Sönnerborg, A, et al.
Publicado: (2010)

Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO
por: Molina, Jean-Michel, et al.
Publicado: (2014)

Psychosocial factors affecting COVID-19 vaccine uptake in the UK: A prospective cohort study (CoVAccS – Wave 3)
por: Smith, Louise E., et al.
Publicado: (2023)

Leveraging WHO’s Global Benchmarking Tool to strengthen capacity in clinical trials oversight for public health emergencies: the GHPP VaccTrain model
por: Owusu Sekyere, Solomon, et al.
Publicado: (2022)

Psychological factors associated with reporting side effects following COVID-19 vaccination: A prospective cohort study (CoVAccS – Wave 3)
por: Smith, Louise E., et al.
Publicado: (2023)

Second European Round Table on the Future Management of HIV: 10–11 October 2014, Barcelona, Spain
por: Rokx, Casper, et al.
Publicado: (2015)

Response to Shami et al. ‘Evaluating the cost-effectiveness of a sequential pneumococcal vaccination compared to single dose vaccination strategy for adults in Hong Kong’ (Hum Vacc Immunother 2020)
por: Buchwald, Ulrike K., et al.
Publicado: (2020)

VACuum INtubation (VACcIN) box restricts the exhaled air dispersion generated by simulated cough: description and simulation-based tests of an innovative aerosolization protective prototype
por: Issa, Rami, et al.
Publicado: (2021)

COVISHIELD (AZD1222) VaccINe effectiveness among healthcare and frontline Workers of INdian Armed Forces: Interim results of VIN-WIN cohort study
por: Ghosh, Subhadeep, et al.
Publicado: (2021)

Side-effect expectations from COVID-19 vaccination: Findings from a nationally representative cross-sectional survey (CoVAccS – wave 2)
por: Smith, Louise E., et al.
Publicado: (2022)

COVID-19 vaccination intention in the UK: results from the COVID-19 vaccination acceptability study (CoVAccS), a nationally representative cross-sectional survey
por: Sherman, Susan M., et al.
Publicado: (2020)

Assessing the immune response to SARS-CoV-2 mRNA vaccines in siponimod-treated patients: a nonrandomized controlled clinical trial (AMA-VACC)
por: Ziemssen, Tjalf, et al.
Publicado: (2022)

Immediate versus deferred antiretroviral therapy in HIV-infected patients presenting with acute AIDS-defining events (toxoplasmosis, Pneumocystis jirovecii-pneumonia): a prospective, randomized, open-label multicenter study (IDEAL-study)
por: Schäfer, Guido, et al.
Publicado: (2019)

Efficacy and tolerability of darunavir/r 600/100 mg bid in treatment-experienced patients: 48-week data from a German outpatient cohort
por: van Lunzen, J, et al.
Publicado: (2010)

National Electronics Conference
por: Asmuth, J L
Publicado: (1961)

VaccHemInf project: protocol for a prospective cohort study of efficacy, safety and characterisation of immune functional response to vaccinations in haematopoietic stem cell transplant recipients
por: Conrad, Anne, et al.
Publicado: (2019)

Is there Emergence of Clinical HBV Resistance Under Long-Term HBV Combination Therapy? A Challenging Case Report
por: Schewe, Knud, et al.
Publicado: (2010)

HIV-induced immune activation - pathogenesis and clinical relevance. Summary of a workshop organised by the German AIDs Society (DAIG e.v.) and the ICH Hamburg, Hamburg, Germany, November 22, 2008
por: Stellbrink, HJ, et al.
Publicado: (2010)

Risk of strong antibody decline in dialysis and transplant patients after SARS-CoV-2mRNA vaccination: Six months data from the observational Dia-Vacc study
por: Stumpf, Julian, et al.
Publicado: (2022)

Immune Response to Initial and Booster SARS-CoV-2 mRNA Vaccination in Patients Treated with Siponimod—Final Analysis of a Nonrandomized Controlled Clinical Trial (AMA-VACC)
por: Ziemssen, Tjalf, et al.
Publicado: (2023)

PedVacc 002: A phase I/II randomized clinical trial of MVA.HIVA vaccine administered to infants born to human immunodeficiency virus type 1-positive mothers in Nairobi
por: Njuguna, Irene N., et al.
Publicado: (2014)

Real World Patient-reported Outcomes in HIV-infected Adults Switching to EVIPLERA(®), Because of a Previous Intolerance to cART. PRO-STR Study
por: Podzamczer, D., et al.
Publicado: (2018)

Brief Report: Switch to Ritonavir-Boosted Atazanavir Plus Raltegravir in Virologically Suppressed Patients With HIV-1 Infection: A Randomized Pilot Study
por: van Lunzen, Jan, et al.
Publicado: (2016)

Potential use of serum‐derived bovine immunoglobulin/protein isolate for the management of COVID‐19
por: Utay, Netanya S., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mvs6ju6re4nhgtjfor9r82dq6b